Aeglea BioTherapeutic: , Including Exhibit 99.1 To This Report, Shall Not Be Deemed To Be Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 2.02 And In The Accompanying Exhibit 99.1 Shall Not Be Incorporated By Reference Into Any Other Filing Under The Exchange Act Or Under The Securities Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing, Regulation Fd Disclosure, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Spyre Therapeutics Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***